Detalhe da pesquisa
1.
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
Cell
; 173(2): 515-528.e17, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29625057
2.
Anatomic position determines oncogenic specificity in melanoma.
Nature
; 604(7905): 354-361, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35355015
3.
Clinical cancer genomic profiling.
Nat Rev Genet
; 22(8): 483-501, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762738
4.
Author Correction: Tumour lineage shapes BRCA-mediated phenotypes.
Nature
; 577(7789): E1, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822847
5.
Tumour lineage shapes BRCA-mediated phenotypes.
Nature
; 571(7766): 576-579, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292550
6.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
7.
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Acta Neuropathol
; 147(1): 85, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38758238
8.
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Gynecol Oncol
; 181: 162-169, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211393
9.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
10.
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Lancet Oncol
; 24(10): 1073-1082, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666264
11.
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
J Urol
; 209(5): 863-871, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724067
12.
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Nature
; 548(7666): 234-238, 2017 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28783719
13.
Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants.
Cancer
; 128(21): 3870-3879, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041233
14.
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Hepatology
; 74(3): 1429-1444, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33765338
15.
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Br J Cancer
; 124(7): 1214-1221, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33473164
16.
Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases.
Ann Surg Oncol
; 28(2): 817-825, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32683635
17.
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Nature
; 518(7538): 240-4, 2015 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25409150
18.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Lancet Oncol
; 21(6): 821-831, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32437664
19.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138866
20.
Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
Cancer
; 126(18): 4126-4135, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32663328